Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity

Abstract : Tumor antigen (TA)-targeting monoclonal antibody (mAb)-based treatments are considered to be one of the most successful strategies in cancer therapy. Besides targeting TAs and inducing tumor cell death, such antibodies interact with immune cells through Fc-dependent mechanisms to induce adaptive memory immune responses. However, multiple inhibitory/immunosuppressive pathways can be induced by tumor cells to limit the establishment of an efficient antitumor response and consequently a sustained clinical response to TA-targeting mAbs. Here, we provide an overview on how TA-targeting mAbs in combination with conventional cancer therapies and/or inhibitors of key immunosuppressive pathways might represent promising approaches to achieve long-term tumor control.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02181343
Contributeur : Cécile Nowak <>
Soumis le : vendredi 12 juillet 2019 - 09:18:16
Dernière modification le : mardi 16 juillet 2019 - 10:48:39

Lien texte intégral

Identifiants

Collections

Citation

Henri-Alexandre Michaud, Jean-Francois Eliaou, Virginie Lafont, Nathalie Bonnefoy, Laurent Gros. Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity. Oncoimmunology, 2014, 3, pp.e955684. ⟨10.4161/21624011.2014.955684⟩. ⟨hal-02181343⟩

Partager

Métriques

Consultations de la notice

11